-+ 0.00%
-+ 0.00%
-+ 0.00%

Damora Therapeutics CEO Jennifer Jarrett acquires $252,875 of common shares

PUBT·09/28/2026 11:00:43
Listen to the news
Damora Therapeutics CEO Jennifer Jarrett acquires $252,875 of common shares
  • Damora Therapeutics director, President and CEO Jennifer Jarrett bought 12,500 ordinary shares in open-market purchases.
  • Shares were acquired at a weighted average price of $20.23.
  • Directly held stake rose to 512,500 ordinary shares following the transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-403355), on September 28, 2026, and is solely responsible for the information contained therein.